Demo Data from EDBT 2026 / reviewers in the wild / expert
Carla Mariner-Llicer
dblp:261/4438
· DBLP profile ↗
1ranked-venue papers
0as first author
0since 2021 · last 2020
—ORCID · unresolved
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 2 heaviest of 2, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology
comparative genomics |
0.4 | 1 | 2020 | Towards next-generation diagnostics for tuberculosis: identification of novel molecular targets by large-scale comparative genomics · Bioinform. 2020 |
Bioinformatics and computational biology › genomics
pathogen genomics |
0.4 | 1 | 2020 | Towards next-generation diagnostics for tuberculosis: identification of novel molecular targets by large-scale comparative genomics · Bioinform. 2020 |
Methods — techniques the papers use, named apart from their topics
qPCR assay design · 0.4
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2020 | Towards next-generation diagnostics for tuberculosis: identification of novel molecular targets by large-scale comparative genomicsabstractMOTIVATION: Tuberculosis (TB) remains one of the main causes of death worldwide. The long and cumbersome process of culturing Mycobacterium tuberculosis complex (MTBC) bacteria has encouraged the development of specific molecular tools for detecting the pathogen. Most of these tools aim to become novel TB diagnostics, and big efforts and resources are invested in their development, looking for the endorsement of the main public health agencies. Surprisingly, no study has been conducted where the vast amount of genomic data available is used to identify the best MTBC diagnostic markers. RESULTS: In this work, we used large-scale comparative genomics to identify 40 MTBC-specific loci. We assessed their genetic diversity and physiological features to select 30 that are good targets for diagnostic purposes. Some of these markers could be used to assess the physiological status of the bacilli. Remarkably, none of the most used MTBC markers is in our catalog. Illustrating the translational potential of our work, we develop a specific qPCR assay for quantification and identification of MTBC DNA. Our rational design of targeted molecular assays for TB could be used in many other fields of clinical and basic research. AVAILABILITY AND IMPLEMENTATION: The database of non-tuberculous mycobacteria assemblies can be accessed at: 10.5281/zenodo.3374377. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Galo A. Goig, Manuela Torres-Puente, Carla Mariner-Llicer, Luis M. Villamayor, Álvaro Chiner-Oms, Ana Gil-Brusola, Rafael Borrás, Iñaki Comas Espadas |
Bioinform. | 3 |